Next Article in Journal
Exploring the Role of Visual Guidance in Motor Imagery-Based Brain-Computer Interface: An EEG Microstate-Specific Functional Connectivity Study
Next Article in Special Issue
Flat Magnetic Stimulation for Stress Urinary Incontinence: A Prospective Comparison Study
Previous Article in Journal
Review on Biomedical Advances of Hybrid Nanocomposite Biopolymeric Materials
Previous Article in Special Issue
Home Spirometry in Children with Cystic Fibrosis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Bioengineering
Volume 10
Issue 3
10.3390/bioengineering10030280
bioengineering-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Inactivation of SARS-CoV-2 on Surfaces by Cold-Plasma-Generated Reactive Species

by
Som V. Thomas
1,
Krista Dienger-Stambaugh
2,
Michael Jordan
2,
Yuxin Wang
1,
Jason Hammonds
2,
Paul Spearman
2,* and
Donglu Shi
1,3,*
1
Department of Biomedical Engineering, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH 45221, USA
2
Division of Infectious Diseases, Cincinnati Children’s Hospital Medical Center and University of Cincinnati, Cincinnati, OH 45229, USA
3
The Materials Science and Engineering Program, Dept. of Mechanical and Materials Engineering, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH 45221, USA
*
Authors to whom correspondence should be addressed.
Bioengineering 2023, 10(3), 280; https://doi.org/10.3390/bioengineering10030280
Submission received: 7 February 2023 / Revised: 16 February 2023 / Accepted: 17 February 2023 / Published: 21 February 2023
(This article belongs to the Special Issue Recent Advances of Medical Devices)
Browse Figures
Versions Notes

Abstract

:
A Cold Atmospheric Plasma (CAP) apparatus was designed and developed for SARS-CoV-2 killing as evaluated by pseudotyped viral infectivity assays. The reactive species generated by the plasma system was fully characterized by using Optical Emission Spectroscopy (OES) measurement under given conditions such as plasma power, flow rate, and treatment time. A variety of reactive oxygen species (ROS) and reactive nitrogen species (RNS) were identified from plasma plume with energies of 15–72 eV in the frequency range between 500–1000 nm. Systematic virus killing experiments were carried out, and the efficacy of CAP treatment in reducing SARS-CoV-2 viral infectivity was significant following treatment for 8 s, with further enhancement of killing upon longer exposures of 15–120 s. We correlated killing efficacy with the reactive species in terms of type, intensity, energy, and frequency. These experimental results demonstrate effective cold plasma virus killing via ROS and RNS under ambient conditions.

1. Introduction

Plasma, one of the four fundamental states of matter, is composed of a combination of neutral atoms, atomic ions, electrons, molecular ions, and excited and ground state molecules [1,2,3]. It can be produced by exposing gas, such as air or argon, to a strong electromagnetic field, which causes negatively charged electrons to dissociate from the nucleus. The charged particles in plasma possess substantial internal energies that can be utilized for altering surfaces. Currently, plasma treatment is utilized in surface and interface engineering to enhance adhesion, hydrophobicity, hydrophilicity, printability, corrosion resistance, selectivity, and for surface etching or cleaning [4,5,6,7,8,9,10,11]. The primary principle behind the plasma technique is that ionized and excited molecules generated by an electrical field directly impact the surface of the substrate. These activated molecules can modify the surface properties of substrates by etching, sputtering, or depositing on them. The plasma technique is an environmentally friendly process performed at room temperature. Therefore, it can be applied for surface modification and thin film deposition on a wide range of substrates such as metals, ceramics, polymer films, paper, glass, and nanoparticles [4,5,6,7,8,9,10,11].
Cold plasma or non-equilibrium plasma is a plasma state in which the electrons and heavier species (ions and neutrals) are not in thermodynamic equilibrium and the temperature of these heavy species (ions and neutrals) is lower than electron temperature [12,13], which is expressed in terms of the energy unit electron volt (eV). Cold atmospheric plasma (CAP) is a powerful tool that can generate ROS, RNS, charged particles, photons, and electric fields for biomedical applications via two mechanisms: “plasma killing” and “plasma healing”. The former is utilized in bacterial sterilization [14], treatment for fungal infection [15], degradation of both organic/inorganic contaminants in water treatment [16], virus inactivation [17], and apoptosis of cancer cells [18], while the latter can be used to enhance cellular oxidation in wound healing and modify surfaces for biological implants (hydrophobic/hydrophilic surface properties) [19]. These in vitro ROS and RNS are also responsible for promoting cell differentiation and apoptosis, as well as other biomolecular activities.
In the realm of biomedical applications, cold atmospheric plasma (CAP) has been employed to combat the COVID-19 pandemic by eliminating the virus [20,21,22,23,24,25]. The transmission of COVID-19 occurs through respiratory droplets originating from infected individuals’ coughs and sneezes. These droplets can contaminate various surfaces such as bedding, floors, walls, and objects, which uninfected individuals may meet. While the Centers for Disease Control and Prevention (CDC) have recommended measures such as the use of hand sanitizers, alcohol, and diluted sodium hypochlorite solutions to prevent such transmission, there is a lack of systematic studies to confirm their effectiveness in killing COVID-19. Additionally, it remains unclear how to effectively control the spread of COVID-19 through disinfection methods for everyday activities. Most disinfectants available are in liquid or gel forms, which are effective on hard surfaces or skin, but not on soft surfaces such as clothing, mail, printed materials, and human hair, which frequently encounter public surfaces and can serve as potential sources of COVID-19 spread if not promptly and adequately disinfected. Thus, it is crucial to develop a “dry” treatment method, such as cold atmospheric plasma, that can be easily and frequently applied to these everyday items.
In this study, we carried out SARS-CoV-2 killing assays using pseudotyped viruses via cold-plasma-generated reactive species in terms of their distributions and time dependencies that could be correlated to different in vitro biological processes. The goal of this study was also to investigate the efficacy of plasma treatment on SARS-CoV-2 pseudotyped viruses by controlling the parameters of the CAP device. We designed and developed a low-pressure plasma system for studies on the efficacy of plasma disinfectant.

2. Experimental Methods

2.1. Plasma Apparatus Design

The schematic diagram of the plasma system is shown in Figure 1a. We utilized a commercial P80 plasma cutting machine straight-handle torch (Figure 1b) with a nozzle diameter of 1.5 mm to produce the cold plasma plume. As shown in Figure 1a, a DC power source (CX-600A, Chengdu Chuangyu Xinjie Technology Co., Ltd., Sichuan, China) was used to drive the CAP torch (Figure 1c), which could produce variable voltage between 5–60 kV, 400 W output. The CAP torch electrode tip was connected as the cathode and the tip nozzle acted as the anode. The applied voltage was measured by using a high voltage probe (Precision USB 100 kV high voltage Probe, CPS HIGH VOLTAGE, Tigard, OR, USA) and the current by using a current monitor (CM-100-S, ION PHYSICS CORPORATION, Fremont, NH, USA); both were connected to a digital oscilloscope (SDS1204X-E—200 MHz/4 Channel, SIGLENT TECHNOLOGIES CO., LTD, Shenzhen, China). The electrical discharge voltage and current were found to be 9.64 kV and 40 mA, respectively.
In the plasma virus killing experiments, the flow rate of the feed gas was controlled using a SmartTrak®100 Digital Mass Flow Controller (Sierra Instruments, Monterey, CA, USA). We applied a high voltage at ~40 kV, current ~8 mA, and fed air (purity: 99.98%) through the plasma nozzle with a flow rate of 7 standard liters per minute (SLPM) to produce a plasma plume under ambient atmosphere (Figure 1c). As shown in Figure 1c, the plasma plume generated was uniform, with a length of about 15 mm and diameter of 5 mm. It could reach the sample well bottom uniformly for effective virus killing. Optical emission spectroscopy (OES) was performed using a photo spectrometer AvaSpec, ULS4096CL-EVO-UA-10 (Avantes, Apeldoorn, The Netherlands) connected to an optical fiber to analyze and identify the reactive species (RS) produced by the CAP torch between wavelengths of 200–1100 nm. Plasus Specline−AMS (Ver 2.1, PLASUS GmbH, Mering, Germany) Plasma characterization software was used to identify individual species with various characteristics such as frequency, energy, and intensity.
The optical emission spectroscopy (OES) measurement was performed by horizontally positioning the optical fiber sensor radially 10 mm away from the tip of the plasma plume nozzle and 10 mm below the nozzle tip (see horizontal red arrow in Figure 2). The height of the optical sensor was varied within 10 mm vertically below the plasma nozzle, as indicated by the red arrow in Figure 2, to determine the plasma strength profile. The purpose of the OES experiment was to identify the types of prevalent RS at different time intervals and air flow rates.

2.2. Virus Construction and Infectivity Experimental Methods

Cell lines: The human embryonic kidney epithelial cell line 293T was obtained from ATCC and cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% heat-inactivated fetal bovine serum (FBS), 1% l-glutamine (Gibco, Waltham, MA, USA), and 100 U/mL penicillin–streptomycin (Gibco). Human-angiotensin-converting enzyme 2 (hACE2) was amplified via PCR and cloned into the Xho1 and Xba1 sites of pLVX-Puro (Clontech, Mountain View, CA, USA), confirmed by DNA sequencing. Lentivirus generated using a third-generation system comprised of pLVX-hACE2-Puro, psPAX2, and pMD2.G (Addgene plasmid # 12260; http://n2t.net/addgene:12260 (accessed on 13 December 2022); RRID:Addgene_12260 and Addgene plasmid # 12259; http://n2t.net/addgene:12259 (accessed on 13 December 2022); RRID:Addgene_12259), gifts from Didier Trono) was utilized to produce a 293T cell line that stably expressed hACE2 under puromycin selection (1.5 µg/mL, Invivogen). Stable expression was confirmed by flow cytometric analysis using hACE2-specific antibodies. Cells were expanded and cryopreserved for use in viral infectivity assays.

2.3. SARS-CoV-2 Pseudotyped Lentivirus Production

Lentivirus was produced in 293T cells utilizing a third-generation three-plasmid system. Single-round lentiviruses were produced by using JetPrime (Polyplus) transfection reagent to co-transfect pTMLW, psPAX2, and a pseudotype envelope expression plasmid, either SARS-CoV-2 (Wuhan strain) spike, pCMV SARS-CoV-2 Spike CΔ19 R682Q [26], or the positive control vesicular stomatitis virus envelope (VSV-G) pMD2.G.
The pTMLW transfer vector contained a 3′ and truncated 5′ long terminal repeat, expressed a firefly luciferase reporter transgene under the control of an RSV promoter, and was a gift from Punam Malik at Cincinnati Children’s Hospital Medical Center. The psPAX2 packaging plasmid ensured replication-incompetent lentivirus production. After 48 h had passed post-transfection, the virus-containing cell culture supernatant was harvested, pooled, and clarified via centrifugation at 2500× g for 10 min at 4 °C. Supernatants were filtered through a 0.45 μm Nalgene filter before being aliquoted, snap-frozen, and stored at −80 °C.

2.4. SARS-CoV-2 Pseudotyped Lentivirus Infectivity Assay

To measure infectivity, hACE2 293T cells were seeded in a 96-well plate and viral supernatants were applied with 5-fold serial dilutions in the presence of 8 μg/mL DEAE-Dextran. We assayed cells for luciferase reporter gene expression at 48 h post-infection by removing 100 μL of culture media and replacing it with 100 μL Britelite substrate (Perkin Elmer, Waltham, MA, USA). The cells, remaining media, and Britelite were mixed until homogenous, then 150 μL of lysate mix was transferred to a black 96-well plate for measurement of emitted light. Luminescence was measured within 10 min using a Bio-Tek Synergy Neo2 luminometer and is reported as the mean RLU of four replicate wells +/− SD. TCID50 values were calculated for quadruplicate samples using Reed–Muench methods. RLUs from uninfected cells were averaged to determine the assay background. Infection positivity was defined as an RLU greater than 2.5 × background RLU [27,28,29].

2.5. Preparation of SARS-CoV-2 Pseudotyped Lentivirus for CAP Treatment

Viral supernatants (100 μL) of known titer were applied to a standard 96-well round-bottom cell culture plate (Corning 351177, Tewksbury, MA, USA). The plate was placed inside of a desiccated chamber within a laminar flow hood and virus supernatant was dried overnight under ambient sterile conditions. The desiccated virus was then subjected to the cold plasma plume for varying time intervals from 0 (untreated) to 120 s. The virus was also treated with non-energized air at 7 SLPM for 120 s to control for any effects that may be due to air turbulence alone. The treated virus was then reconstituted in 100 μL of cell culture medium and tested at various dilutions for infectivity in the SARS-CoV-2 pseudotyped lentivirus infectivity assay.

3. Results

3.1. Spectroscopy Characterization of Cold Plasma-Generated Reactive Species

We carried out OES experiments at a flow rate of 7 SLPM, with spectroscopic analysis at 0 s and 15 s. Figure 3 shows various plasma reactive species produced at 0 s (Figure 3a) and 15 s (Figure 3b). Reactive oxygen and nitrogen species (RONS) include two classes of chemically reactive molecules containing oxygen (reactive oxygen species, ROS) and nitrogen (reactive nitrogen species, RNS). Both classes are referred to as RONS. The majority of RONS carries unpaired electrons, also known as free radicals. As can be seen in this figure, both ROS and RNS were generated at different wavelengths and intensities. Numerous RONS were observed at both 0 s and 15 s, indicating their prevalent and frequent appearance under plasma excitation.
Table 1 and Table 2 summarize the parameters of RONS at 0 s and 15 s, respectively, including wavelengths, intensity, ionic species excited state (single/multiple), identified lines, relative intensity, energy (lower/upper), transition state (lower/upper), and quantum number (lower/upper). In these tables, N I, N II, N III and O I, O II, OIII, OIV debnote RNS and ROS, respectively.
As shown in Table 1 and Table 2, there are numerous ROS and RNS at 0 and 15 s with different characteristics. While the energies of ROS are generally higher (~29–72 eV), those of RNS tend to be smaller (~12–43 eV). From Figure 3, Table 1 and Table 2, one can see significant RONS being generated by plasma, which could be responsible for virus killing or deactivation.
To verify that the plasma treatment was performed at ambient temperature, the temperature profiles of the experimental set up were monitored using a thermal camera (Benchtop PCB Thermal Imaging Camera, Teslong 260 × 200 Infrared Thermal Analyzer, Irvine, CA, USA). Figure 4 shows the thermal images of the CAP torch (Figure 4a) and microwell assay plate where the viruses are contained (Figure 4b). As shown in Figure 4a, the temperature of the plasma nozzle was 30 °C, while that at the assay well area was 25.7 °C (Figure 4b). These thermal images indicate that the plasma was at room temperature, which is characteristic of CAP.

3.2. SARS-CoV-2 Pseudotyped Viral Infectivity Assays

To develop a suitable model of surface contamination, we applied SARS-CoV-2 pseudotyped virus to a polystyrene surface and demonstrated that infectious virus was still present even after overnight desiccation under ambient conditions. We used a VSV-G-pseudotyped lentivirus as a positive control for the infectivity assays. We also controlled for the potential displacement of virus from the solid surface due to air pressure alone that was generated during CAP treatment. The infectivity assay performed as expected, based on the ability of VSV-G-pseudotyped virus to infect cells at a high TCID50. We did not observe any decrease in viral infectivity after treatment of viruses with air alone, as compared to virus that was only desiccated (data not shown).
Based on the plasma setup (Figure 1) and RONS characterization (Figure 3, Table 1 and Table 2), we conducted cold plasma treatment of SARS-CoV2 spike pseudotyped virus. We confirmed that the cold plasma plume was not above ambient temperature, and the plume length was sufficient to reach the bottom of the assay well containing desiccated virus. Figure 5a shows the infectivity assay results measured as luciferase counts (RLU) at various dilutions of the air-treated control viral inoculum as well as the inoculum after treatment with CAP for the indicated times. Measurement of luciferase activity over multiple dilutions allowed for calculation of the TCID50. Figure 5b shows the calculated TCID50 for each condition measured in Figure 5a, revealing a substantial reduction in remaining infectious units following treatment at 8 s and further reduction upon longer treatment.
To illustrate the reproducibility and efficiency of killing, the data from Figure 5b are presented as percentage reduction in infectivity in Figure 6. Cold plasma treatment resulted in a mean reduction in infectivity of 79% in as little as 8 s that increased to 93% by 15 s (n = 2). Further reduction occurred at 30 and 60 s, with a sustained mean reduction of 97% infectivity, and a near return to background RLU with 99% reduction at 120 s (n = 5). As is evident from this figure, even very short times of application of the plasma plume to the surface resulted in a significant reduction in infectivity.

4. Discussion

Cold atmospheric plasma (CAP) has been investigated for its potential to inactivate SARS-CoV-2, the virus responsible for COVID-19 [30,31,32]. Studies have shown that CAP can effectively inactivate SARS-CoV-2 on surfaces and in the air. The mechanism by which CAP inactivates the virus is not yet fully understood, but it is thought to involve the production of reactive oxygen and nitrogen species (RONS) that can damage the virus’s genetic material, rendering it unable to infect cells. Prior research indicates that RONS can cause harm to various cellular organelles and biological processes [33,34,35]. Nevertheless, RONS can also serve as a signaling molecule within host cells, prompting the activation of immune responses to combat viral infections. For instance, RONS produced by the host cells can stimulate the inflammasome, a protein complex that prompts the production of cytokines. These signaling molecules activate immune cells to counter the virus. On the other hand, RONS can impede viral infections by directly impairing the virus’s genetic material, reducing its infectiousness. That being said, RONS can result in oxidative stress within host cells, causing cellular damage, inflammation, and apoptosis [36,37,38].
As shown in Table 1 and Table 2, under different plasma conditions, RONS were directly generated in the plasma discharge zone. Both reactive oxygen species (ROS) and reactive nitrogen species (RNS) are excited/neutral molecules containing a minimum of one oxygen atom and single/multiple unpaired electrons. These ensembles consist of free radicals such as superoxide anion, hydroxyl, hydroperoxyl, singlet/doublet/triplet/quartet oxygen, free nitrogen, and free hydrogen species in some cases. The production of a surplus of free species adds to oxidative stress on the cell surface, inducing molecular- and cellular-level impairment of structures. These in vitro ROS and RNS become signaling molecules when impinging on the cellular surface, leading to chemical imbalances and disruptive effects to proteins (aggregation, denaturation), lipids (peroxidation), carbohydrates, and nucleotides (changes in the DNA structure) of the cellular species. As also shown in Table 1 and Table 2, the intensities of RONS are significantly high, with a maximum on the order of ~70 eV for ROS and ~40 eV for RNS responsible for significant virus killing efficacies within a short period of time.
Infection of ACE2 expressing cells by SARS-CoV-2 relies on the trimeric SARS-CoV-2 spike glycoprotein. We produced a lentivirus bearing a structurally and functionally similar spike glycoprotein as a surrogate for the SARS-CoV-2 virus itself, which requires BSL3 conditions for cultivation and quantitation. Pseudotyped viruses were easily recoverable from a dry surface, providing a readily quantified measure of infectivity from untreated or CAP-treated wells. Our results demonstrate the ability of CAP to diminish viral infectivity in a time-dependent manner in this sensitive and quantitative assay. The efficacy of CAP treatment on SARS-CoV-2 viral infectivity was highly reproducible. Cold plasma treatment for as little as 8 s produced significant killing, while killing of residual infectious virus was further enhanced upon longer exposures. Application of the treatment for 120 s effectively reduced infectivity measurement to background levels (100% killing). We recognize that the shorter times of application (8–15 s) will be more practical for future applications of the technology as a mode of reducing virus transmission from surfaces.

5. Conclusions

We found numerous reactive oxygen and nitrogen species (RONS) in a wide spectrum of frequencies with high energies that were the most likely to be responsible for virus killing. Experimental results from this study provide proof of concept for the ability of cold plasma to inactivate SARS-CoV-2 on surfaces. One key outcome of this study is the correlation between the virus killing efficacy and the reactive species that are generated by the plasma device. This plasma system was fully characterized by the reactive species generated under different conditions such as flow rate and time. The new methods to generate a stable and effective cold atmospheric plasma plume were shown to be effective, as evidenced by the results of killing SARS-CoV-2 pseudovirus. Future studies are needed to expand on the work described here, including application of cold plasma against other enveloped viruses on surfaces and potentially the identification of the particular RONS that are most effectively deployed for the inactivation of viruses.

Author Contributions

S.V.T. and K.D.-S. are joint first authors and contributed equally to this manuscript. Conceptualization, D.S. and P.S.; methodology, J.H., D.S., P.S., S.V.T., K.D.-S., M.J. and Y.W.; software, S.V.T.; validation, D.S., P.S., S.V.T., K.D.-S., M.J. and Y.W.; formal analysis, D.S., P.S., S.V.T., K.D.-S., M.J. and Y.W., investigation, D.S., P.S., S.V.T., K.D.-S., M.J. and Y.W.; resources, J.H., D.S. and P.S.; data curation, S.V.T., K.D.-S., M.J. and Y.W.; writing—original draft preparation D.S., P.S., S.V.T. and K.D.-S.; writing—review and editing, D.S., P.S., S.V.T. and K.D.-S.; supervision, D.S., P.S. and K.D.-S.; project administration, D.S. and P.S.; funding acquisition, D.S. and P.S. All authors have read and agreed to the published version of the manuscript.

Funding

We acknowledge the financial support from National Science Foundation 2029268.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are available in a publicly accessible repository.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Chu, P.K.; Lu, X. (Eds.) Low Temperature Plasma Technology: Methods and Applications; CRC Press: Boca Raton, FL, USA, 2013. [Google Scholar]
  2. Piel, A.; Brown, M. Plasma physics: An introduction to laboratory, space, and fusion plasmas. Phys. Today 2011, 64, 55. [Google Scholar]
  3. Chen, F.F. Introduction to Plasma Physics and Controlled Fusion; Plenum Press: New York, NY, USA, 1984; Volume 1, pp. 19–51. [Google Scholar]
  4. Shi, D.; Lian, J.; He, P.; Wang, L.M.; Xiao, F.; Yang, L.; Schulz, M.J.; Mast, D.B. Plasma coating of carbon nanofibers for enhanced dispersion and interfacial bonding in polymer composites. Appl. Phys. Lett. 2003, 83, 5301–5303. [Google Scholar] [CrossRef] [Green Version]
  5. Zhao, J.; Schaefer, D.W.; Shi, D.; Lian, J.; Brown, J.; Beaucage, G.; Wang, L.; Ewing, R.C. How does surface modification aid in the dispersion of carbon nanofibers? J. Phys. Chem. B 2005, 109, 23351–23357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Shi, D.; He, P.; Wang, S.X.; Van Ooij, W.J.; Wang, L.M.; Zhao, J.; Yu, Z. Interfacial particle bonding via an ultrathin polymer film on Al2O3 nanoparticles by plasma polymerization. J. Mater. Res. 2002, 17, 981–990. [Google Scholar] [CrossRef] [Green Version]
  7. Shi, D.; Lian, J.; He, P.; Wang, L.M.; van Ooij, W.J.; Schulz, M.; Liu, Y.; Mast, D.B. Plasma deposition of ultrathin polymer films on carbon nanotubes. Appl. Phys. Lett. 2002, 81, 5216–5218. [Google Scholar] [CrossRef] [Green Version]
  8. Shi, D.; Wang, S.X.; van Ooij, W.J.; Wang, L.M.; Zhao, J.; Yu, Z. Uniform deposition of ultrathin polymer films on the surfaces of Al 2 O 3 nanoparticles by a plasma treatment. Appl. Phys. Lett. 2001, 78, 1243–1245. [Google Scholar] [CrossRef]
  9. Shi, D.; Lian, J.; Peng, H.; Wang, W.; Dong, Z.; Wang, L.; Ewing, R.C. Luminescent Carbon Nanotubes. Adv. Mater. 2006, 18, 189–193. [Google Scholar] [CrossRef]
  10. Guo, Y.; Cho, H.; Shi, D.; Lian, J.; Song, Y.; Abot, J.; Poudel, B.; Ren, Z.; Wang, L.; Ewing, R.C. Effects of plasma surface modification on interfacial behaviors and mechanical properties of carbon nanotube-Al2O3 nanocomposites. Appl. Phys. Lett. 2007, 91, 261903. [Google Scholar] [CrossRef]
  11. Cho, H.; Shi, D.; Guo, Y.; Lian, J.; Ren, Z.; Poudel, B.; Song, Y.; Abot, J.L.; Singh, D.; Routbort, J.; et al. Enhanced thermal stability of carbon nanotubes by plasma surface modification in Al2O3 composites. J. Appl. Phys. 2008, 104, 074302. [Google Scholar] [CrossRef]
  12. Chaudhary, K.; Imam, A.M.; Rizvi, S.Z.H.; Ali, J. Plasma Kinetic Theory. In Kinetic Theory; InTech: Rijeka, Croatia, 2018; p. 107. ISBN 978-953-51-3801-3. [Google Scholar]
  13. Sakudo, A.; Yagyu, Y.; Onodera, T. Disinfection and sterilization using plasma technology: Fundamentals and future perspectives for biological applications. Int. J. Mol. Sci. 2019, 20, 5216. [Google Scholar] [CrossRef] [Green Version]
  14. Annunziata, M.; Canullo, L.; Donnarumma, G.; Caputo, P.; Nastri, L.; Guida, L. Bacterial inactivation/sterilization by argon plasma treatment on contaminated titanium implant surfaces: In vitro study. Med. Oral Patol. Oral Cirugía Bucal 2016, 21, e118. [Google Scholar] [CrossRef] [PubMed]
  15. Misra, N.N.; Yadav, B.; Roopesh, M.S.; Jo, C. Cold plasma for effective fungal and mycotoxin control in foods: Mechanisms, inactivation effects, and applications. Compr. Rev. Food Sci. Food Saf. 2019, 18, 106–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Gururani, P.; Bhatnagar, P.; Bisht, B.; Kumar, V.; Joshi, N.C.; Tomar, M.S.; Pathak, B. Cold plasma technology: Advanced and sustainable approach for wastewater treatment. Environ. Sci. Pollut. Res. 2021, 28, 65062–65082. [Google Scholar] [CrossRef] [PubMed]
  17. Chen, Z.; Garcia, G., Jr.; Arumugaswami, V.; Wirz, R.E. Cold atmospheric plasma for SARS-CoV-2 inactivation. Phys. Fluids 2020, 32, 111702. [Google Scholar] [CrossRef]
  18. Yadav, D.K.; Adhikari, M.; Kumar, S.; Ghimire, B.; Han, I.; Kim, M.H.; Choi, E.H. Cold atmospheric plasma generated reactive species aided inhibitory effects on human melanoma cells: An in vitro and in silico study. Sci. Rep. 2020, 10, 3396. [Google Scholar] [CrossRef] [Green Version]
  19. Fukuda, N.; Tsuchiya, A.; Toita, R.; Tsuru, K.; Mori, Y.; Ishikawa, K. Surface plasma treatment and phosphorylation enhance the biological performance of poly (ether ether ketone). Colloids Surf. B Biointerfaces 2019, 173, 36–42. [Google Scholar] [CrossRef] [PubMed]
  20. Chen, Z.; Bai, F.; Jonas, S.J.; Wirz, R.E. Cold atmospheric plasma for addressing the COVID-19 pandemic. Plasma Process. Polym. 2022, 19, 2200012. [Google Scholar] [CrossRef]
  21. Zhang, X.; Li, X.; Li, Y.; Ma, Y.; Su, X.; Xue, Y.; Liu, D. Inactivation of SARS-CoV-2 by Cold At-mospheric. Plasma. Matter. 2021, 4, 1752–1765. [Google Scholar]
  22. Zhang, H.; Chen, M.; Huang, L.; Guo, L.; Xu, S.; Zhang, J.; Xi, W.; Wang, Z.; Liu, D.; Kong, M.G.; et al. Using cold atmospheric plasma treated-air for COVID-19 disinfection in cold-chain environment. J. Phys. D Appl. Phys. 2021, 54, 40LT01. [Google Scholar] [CrossRef]
  23. Cortázar, O.D.; Megía-Macías, A.; Moreno, S.; Brun, A.; Gómez-Casado, E. Vulnerability of SARS-CoV-2 and PR8 H1N1 virus to cold atmospheric plasma activated media. Sci. Rep. 2022, 12, 263. [Google Scholar] [CrossRef]
  24. Assadi, I.; Guesmi, A.; Baaloudj, O.; Zeghioud, H.; Elfalleh, W.; Benhammadi, N.; Khezami, L.; Assadi, A.A. Review on inactivation of airborne viruses using non-thermal plasma technologies: From MS2 to coronavirus. Environ. Sci. Pollut. Res. 2022, 29, 4880–4892. [Google Scholar] [CrossRef] [PubMed]
  25. Yan, D.; Malyavko, A.; Wang, Q.; Ostrikov, K.; Sherman, J.H.; Keidar, M. Multi-modal biological destruction by cold atmospheric plasma: Capability and mechanism. Biomedicines 2021, 9, 1259. [Google Scholar] [CrossRef] [PubMed]
  26. Johnson, M.C.; Lyddon, T.D.; Suarez, R.; Salcedo, B.; Lepique, M.; Graham, M.; Ricana, C.; Robinson, C.; Ritter, D.G. Optimized pseudotyping conditions for the SARS-CoV-2 spike glycoprotein. J. Virol. 2020, 94, e01062-20. [Google Scholar] [CrossRef] [PubMed]
  27. Sarzotti-Kelsoe, M.; Bailer, R.T.; Turk, E.; Lin, C.L.; Bilska, M.; Greene, K.M.; Gao, H.; Todd, C.A.; Ozaki, D.A.; Seaman, M.S.; et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV. J. Immunol. Methods 2014, 409, 131–146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Hammonds, J.; Chen, X.; Fouts, T.; DeVico, A.; Montefiori, D.; Spearman, P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol. 2005, 79, 14804–14814. [Google Scholar] [CrossRef] [Green Version]
  29. Xing, L.; Wang, S.; Hu, Q.; Li, J.; Zeng, Y. Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents. J. Virol. Methods 2016, 233, 56–61. [Google Scholar] [CrossRef]
  30. Loizou, C.; Kniazeva, V.; Apostolou, T.; Kornev, A.; Kostevitch, S.; Roslyakov, E.; Constantinou, C.; Hadjihannas, L. Effect of Cold Atmospheric Plasma on SARS-CoV-2 Inactivation: A Pilot Study in the Hospital Environment. COVID 2022, 2, 1396–1404. [Google Scholar] [CrossRef]
  31. Bisag, P.A.; Isabelli, G.; Laghi, R.; Laurita, G.; Dirani, F.; Taddei, C.; Bucci, F.; Capelli, M.; Gherardi, A.; Paglianti, V.; et al. Cold atmospheric plasma decontamination of SARS-CoV-2 bioaerosols. Plasma Process. Polym. 2022, 19, e2100133. [Google Scholar] [CrossRef]
  32. Mohamed, H.; Nayak, G.; Rendine, N.; Wigdahl, B.; FC, K.; Bruggeman, P.J.; Miller, V. Non-Thermal Plasma as a Novel Strategy for Treating or Preventing Viral Infection and Associated Disease. Front. Phys. 2021, 9, 683118. [Google Scholar] [CrossRef]
  33. Kaushik, N.; Mitra, S.; Baek, E.J.; Nguyen, L.N.; Bhartiya, P.; Kim, J.H.; Choi, E.H.; Kaushik, N.K. The inactivation and destruction of viruses by reactive oxygen species generated through physical and cold atmospheric plasma techniques: Current status and perspectives. J. Adv. Res. 2022, 38, 143–155. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, P.; Zhou, R.; Zhou, R.; Li, W.; Weerasinghe, J.; Chen, S.; Rehm, B.H.A.; Zhao, L.; Frentiu, F.D.; Zhang, Z.; et al. Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. Theranostics 2022, 12, 2811. [Google Scholar] [CrossRef] [PubMed]
  35. Yan, D.; Sherman, J.H.; Keidar, M.; Laroussi, M. Plasma for virus inactivation: Historical perspectives and modern developments. Plasma Sources Sci. Technol. 2021, 30, 033001. [Google Scholar]
  36. Nathan, C.; Cunningham-Bussel, A. Beyond oxidative stress: An immunologist’s guide to reactive oxygen species. Nat. Rev. Immunol. 2013, 13, 349–361. [Google Scholar] [CrossRef] [Green Version]
  37. Rahman, I.; MacNee, W. Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. 2000, 16, 534–554. [Google Scholar] [CrossRef]
  38. Circu, M.L.; Aw, T.Y. Reactive oxygen species, cellular redox systems, and apoptosis. Free. Radic. Biol. Med. 2010, 48, 749–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Bioengineering 10 00280 g001 550
Figure 1. Schematic of diagrams: (a) the plasma apparatus design, (b) the P80 plasma cutting machine straight-handle torch, and (c) the plasma plume produced at room temperature under ambient pressure.
Figure 1. Schematic of diagrams: (a) the plasma apparatus design, (b) the P80 plasma cutting machine straight-handle torch, and (c) the plasma plume produced at room temperature under ambient pressure.
Bioengineering 10 00280 g001
Bioengineering 10 00280 g002 550
Figure 2. Photograph showing the experimental setup for the optical emission spectroscopy (OES) measurement.
Figure 2. Photograph showing the experimental setup for the optical emission spectroscopy (OES) measurement.
Bioengineering 10 00280 g002
Bioengineering 10 00280 g003 550
Figure 3. Intensity vs. wavelength for oxygen and nitrogen species generated by plasma at (a) 0 s and (b) 15 s with flow rate 7 SLPM.
Figure 3. Intensity vs. wavelength for oxygen and nitrogen species generated by plasma at (a) 0 s and (b) 15 s with flow rate 7 SLPM.
Bioengineering 10 00280 g003
Bioengineering 10 00280 g004 550
Figure 4. Thermal images of CAP torch and microwell plate. (a) The maximum temperature at the nozzle is 30 °C. (b) Assay well area measured inside the rectangle is 25.7 °C.
Figure 4. Thermal images of CAP torch and microwell plate. (a) The maximum temperature at the nozzle is 30 °C. (b) Assay well area measured inside the rectangle is 25.7 °C.
Bioengineering 10 00280 g004
Bioengineering 10 00280 g005 550
Figure 5. (a) RLU vs. reciprocal dilution for the SARS-CoV-2 pseudovirus infectivity assay, (b) TCID50 vs. CAP treatment time.
Figure 5. (a) RLU vs. reciprocal dilution for the SARS-CoV-2 pseudovirus infectivity assay, (b) TCID50 vs. CAP treatment time.
Bioengineering 10 00280 g005
Bioengineering 10 00280 g006 550
Figure 6. % Reduction in infectivity vs. CAP treatment time.
Figure 6. % Reduction in infectivity vs. CAP treatment time.
Bioengineering 10 00280 g006
Table
Table 1. Reactive species identified via OES at 7 slpm at 0 s, with 30 RNS and 18 ROS.
Table 1. Reactive species identified via OES at 7 slpm at 0 s, with 30 RNS and 18 ROS.
Wave-Length (nm)Intensity
[(µW/cm2)/nm]		Element *Line Identified (nm)I
(Rel.)		Energy (eV)
Lower–Upper		Transition
Lower–Upper		Quantum Number
Lower–Upper
580.2411121.53N I580.2836411.84–13.983p 4P–5d 4F2½–2½
580.2411121.53N I580.3043312.13–14.263p 2P–8s 2P1½–1½
631.294820.914N II631.38091025.65–27.624p ¹S–6s 3P°0–1
670.8311775.77N I670.87591311.84–13.693p 4P°–4d 4D1½–1½
670.8311775.77O III670.736247.03–48.874d 3D°–3s 3D2–3
670.8311775.77O IV670.866271.54–73.393s 4P–4d 4D°1½–½
670.8311775.77O IV670.8661271.54–73.393s 4P–4d 4D°1½–1½
729.6471512.35O II729.6294028.86–30.563d 4D–4p 4P°3½–2½
735.934895.199N I736.0126112.01–13.693p 2D°–4d 2D2½–1½
749.6331197.4N I749.7122013.24–14.904p 4D–3d’ 2G2½–3½
829.6251541.9N I829.6007312.13–13.623p 2P–5s 4P1½–1½
829.6251541.9N II829.6212423.57–25.073d ¹P°–4p ¹P1–1
838.0841246.14O II838.17719430.47–31.954p 4D°–5s 4P½–½
838.0841246.14O III838.036145.44–46.924p 3D–3p 3P°1–1
858.3461166.76O III858.3618454.37–55.824p’ 5D°–4d’ 5P4–3
898.4151465.49N II898.32771326.03–27.414d ¹D°–5f 2[2½]2–3
932.6921845.99O II932.745320531.63–32.964d 4P–5f 4D°1½–½
945.7432754.02O II945.7893428.51–29.823p 2D°–4s 2P2½–1½
945.7432754.02O II945.84291728.51–29.823p’ 2D°–4s 2P2½–1½
981.9811702.36O II982.0556330.80–32.064p 2P°–5s 2P½–1½
981.9811702.36O III982.0475445.94–47.204p 3P–4d 3P°2–2
981.9811702.36O IV981.895173.96–75.224f 4D–3p 4P°1½–2½
1001.811674.33N I1001.7833411.76–12.993p 4D°–3d 2F2½–2½
1001.811674.33N II1001.903126.21–27.454f’ 2[4½]–5g’ 2[2½]°4–3
1020.21266.48N I1020.112113.68–14.904f 2D [3]–3d’ 2G3½–4½
1020.21266.48N I1020.113213.68–14.904f 2D[3]–3d’ 2G2½–3½
1020.21266.48N I1020.122013.68–14.904f 2D[3]–3d’ 2G3½–3½
1020.21266.48O II1020.23129.59–30.804s 4P–4p 2P°½–½
1022.121643.94N I1022.089313.20–14.414p 2S–10d 4P½–½
1022.121643.94N I1022.089113.20–14.414p 2S–10d 4P½–1½
1032.25884.052O II1032.284130.75–31.954p 2D°–5s 4P1½–½
1032.25884.052O III1032.17745444.28–45.484s 3P°–4p 3D2–3
1036.631342.98N I1036.569611.84–13.033p 4P–3d 2D½–1½
1036.631342.98N I1036.574213.26–14.464p 4P–12d 2D½–1½
1036.631342.98O III1036.68713444.24–45.444s 3P°–4p 3D1–1
1051.371579.21N I1051.34130011.84–13.023p 4P°–3d 4D½–½
1058.731288.58N I1058.655413.25–14.424p 4D–12s 4P3½–2½
1058.731288.58N I1058.7843913.29–14.464p 2D–12d 2D1½–1½
1058.731288.58N III1058.81246.72–47.894p 4D–4d 4P°1½–2½
1058.731288.58O II1058.831031.76–32.934f 4F°–5d 2F4½–3½
1069.351383.91N I1069.278113.24–14.404p 4D–10d 4D2½–1½
1069.351383.91N I1069.278413.24–14.404p 4D–10d 4D2½–2½
1069.351383.91N I1069.278213.24–14.404p 4D–10d 4D2½–3½
1069.351383.91N I1069.3175611.84–13.003p 4P–3d 2F2½–3½
1069.351383.91N I1069.424013.24–14.404p 4D–11s 2P½–1½
1069.351383.91N I1069.424213.24–14.404p 4D–11s 2P½–½
1091.321964.13N I1091.364111.84–12.983p 4P–3d 2P1½–½
1092.952458.16N I1092.991213.20–14.344p 2S–8d 4D½–½
*: N I, N II, N III and O I, O II, OIII, OIV are denoted RNS and ROS, respectively.
Table
Table 2. Reactive oxygen species identified via OES at 7 slpm at 15 s, with 20 RNS and 15 ROS.
Table 2. Reactive oxygen species identified via OES at 7 slpm at 15 s, with 20 RNS and 15 ROS.
Wave-Length (nm)Intensity
[(µW/cm2)/nm]		Element *Line Identified (nm)I
(Rel.)		Energy (eV)
Lower-Upper		Transition
Lower-Upper		Quantum Number
Lower-Upper
670.8311345.65N I670.87591311.84–13.693p 4P°–4d 4D1½–1½
670.8311345.65O III670.736247.03–48.874d 3D°–3s 3D2–3
670.8311345.65O IV670.866271.54–73.393s 4P–4d 4D°1½–½
670.8311345.65O IV670.8661271.54–73.393s 4P–4d 4D°1½–1½
735.9341339.33N I736.0126112.01–13.693p 2D°–4d 2D2½–1½
749.6331323.49N I749.7122013.24–14.904p 4D–3d’ 2G2½–3½
759.8921057O II759.82851528.86–30.493d 4D–4p 4D°1½–2½
759.8921057O II759.856428.86–30.493d 4D–4p 4D°1½–2½
759.8921057O II759.91982428.86–30.493d 4D–4p 4D°2½–2½
759.8921057O II759.938411028.86–30.493d 4D–4p 4D°2½–2½
759.8921057O II759.9407031.32–32.953d’ 2G–5f 2G°4½–3½
768.715888.608N III768.7057398242.40–44.015d 2D–6f 2F°2½–3½
803.055851.363N I802.9967112.12–13.673p 2P–4d 2P½–1½
829.625981.434N I829.6007312.13–13.623p 2P–5s 4P1½–1½
829.625981.434N II829.6212423.57–25.073d ¹P°–4p ¹P1–1
838.648745.261N III838.6398536.86–38.333s 2P°–3p 2P1½–1½
844.5631276.25N III844.5766442.54–44.015g 2G–6f 2F°3½–3½
844.5631276.25N III844.576610842.54–44.015g 2G–6f 2F°4½–3½
844.5631276.25O I844.62471159.52–10.993s 3S°–3p 3P1–0
844.5631276.25O I844.63595749.52–10.993s 3S°–3p 3P1–2
932.6921637.01O II932.745320531.63–32.964d 4P–5f 4D°1½–½
973.976747.988N I974.0385010.33–11.603s 4P–3p 2S1½–½
981.4291722.65N I981.40211311.76–13.023p 4D°–3d 4D2½–3½
981.4291722.65O III981.3692045.99–47.254p ¹D–4d ¹P°2–1
1022.941080.7N II1022.867226.21–27.424f’ 2[4½]–5g 2[3½]°5–4
1022.941080.7O II1022.999231.75–32.964f 4F°–5d 2D1½–2½
1032.81059.48O II1032.772031.76–32.964fF 2[4]°–5g 2[5]4½–5½
1071.522159.25N I1071.526513.27–14.434p 4P–11d 4D2½–3½
1071.522159.25N I1071.526013.27–14.434p 4P–11d 4D2½–1½
1071.522159.25N I1071.526113.27–14.434p 4P–11d 4D2½–2½
1083.19776.701O II1083.24439932.94–34.095f 4G°–4d’ 2D3½–2½
1089.431450.25N I1089.399113.24–14.384p 4D–10s 4P1½–2½
1089.431450.25N I1089.437213.24–14.384p 4D–9d 2D2½–2½
1089.431450.25N I1089.476213.24–14.384p 2D–11d 2F1½–2½
*: N I, N II, N III and O I, O II, OIII, OIV denote RNS and ROS, respectively.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Thomas, S.V.; Dienger-Stambaugh, K.; Jordan, M.; Wang, Y.; Hammonds, J.; Spearman, P.; Shi, D. Inactivation of SARS-CoV-2 on Surfaces by Cold-Plasma-Generated Reactive Species. Bioengineering 2023, 10, 280. https://doi.org/10.3390/bioengineering10030280

AMA Style

Thomas SV, Dienger-Stambaugh K, Jordan M, Wang Y, Hammonds J, Spearman P, Shi D. Inactivation of SARS-CoV-2 on Surfaces by Cold-Plasma-Generated Reactive Species. Bioengineering. 2023; 10(3):280. https://doi.org/10.3390/bioengineering10030280

Chicago/Turabian Style

Thomas, Som V., Krista Dienger-Stambaugh, Michael Jordan, Yuxin Wang, Jason Hammonds, Paul Spearman, and Donglu Shi. 2023. "Inactivation of SARS-CoV-2 on Surfaces by Cold-Plasma-Generated Reactive Species" Bioengineering 10, no. 3: 280. https://doi.org/10.3390/bioengineering10030280

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop